Hepatic natural killer T‐cell and CD8+ T‐cell signatures in mice with nonalcoholic steatohepatitis

Hepatic inflammation is a key pathologic feature of nonalcoholic steatohepatitis (NASH). Natural killer T (NKT) cells and clusters of differentiation (CD)8+ T‐cells are known to play an important role in obesity‐related adipose tissue inflammation. We hypothesized that these same inflammatory phenotypes would be present in progressive NASH. We used a previously established high‐fat high‐carbohydrate (HFHC) murine obesogenic diet model of progressive NASH to investigate the role of NKT cells and CD8+ T‐cells in C57Bl6/J mice. To better understand the impact of these cell populations, CD1d‐deficient and CD8+ T‐cell‐depleted mice were subjected to an HFHC diet for 16 weeks. C57Bl6/J mice fed an HFHC diet had increased body weight, liver triglyceride content, serum alanine aminotransferase levels, and increased NKT‐cell and CD8+ T‐cell infiltration in the liver. In addition, human liver sections from patients with NASH showed increased CD8+ T‐cells. In comparison, CD1d‐deficient and CD8 T‐cell‐depleted mice fed an HFHC diet had a lower hepatic triglyceride content, lower alanine aminotransferase levels, lower activated resident macrophages and infiltrating macrophages, improved nonalcoholic fatty liver disease activity scores, and reduced α‐smooth muscle actin, collagen type 1 alpha 1, and collagen type 1 alpha 2 messenger RNA expression. Further, while CD1d‐deficient mice were protected against weight gain on the HFHC diet, CD8 T‐cell‐depleted mice gained weight on the HFHC diet. Conclusion: We found that NASH has an immunological signature that includes hepatic infiltrating NKT and CD8+ T‐cells. Depletion of these cells resulted in reduced NASH progression and thus presents novel therapeutic avenues for the treatment of NASH. (Hepatology Communications 2017;1:299–310)

• Publication year

  2017

• Venue

  Hepatology Communications

• Publication date

  2017-05-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep4.1041PMID 29152605PMCID 5687094
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.

  2016cited by this paper
• Immunotherapeutic implications of IL-6 blockade for cytokine storm.

  2016cited by this paper
• Role of neutralizing anti-murine interleukin-17A monoclonal antibody on chronic ozone-induced airway inflammation in mice.

  2016cited by this paper
• NK cells link obesity-induced adipose stress to inflammation and insulin resistance

  2015cited by this paper
• Nonalcoholic fatty liver disease – current status and future directions

  2015influential reference
• Role of immunodeficient animal models in the development of fructose induced NAFLD.

  2014cited by this paper
• Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.

  2014cited by this paper
• Antigen peptide transporter 1 is involved in the development of fructose‐induced hepatic steatosis in mice

  2013cited by this paper
• NAFLD, NASH and liver cancer

  2013influential reference
• NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications

  2012influential reference
• Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

  2011cited by this paper
• The Interaction between Regulatory T Cells and NKT Cells in the Liver: A CD1d Bridge Links Innate and Adaptive Immunity

  2011cited by this paper
• High‐fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis

  2010influential reference
• CD8+ T cells drive adipose tissue inflammation--a novel clue for NASH pathogenesis?

  2010cited by this paper
• Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease

  2010cited by this paper
• CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity

  2009cited by this paper
• Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.

  2004cited by this paper
• Nonalcoholic steatohepatitis

  2004cited by this paper
• Mechanism of CD1d-restricted natural killer T cell activation during microbial infection

  2003cited by this paper
• IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1

  2002cited by this paper
• In Vivo Depletion of CD4‐ and CD8‐Specific T Cells

  1992cited by this paper

• Acetylshikonin mitigates diet-induced MASLD by targeting PPARγ-mediated metabolic dysfunction

  2026cites this paper
• The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2026cites this paper
• Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies

  2025cites this paper
• Potential mechanisms of natural metabolites and botanical drugs foumulae for the treatment of non-alcoholic fatty liver disease: targeting the gut microbiota to modulate the immune system

  2025cites this paper
• Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota

  2025cites this paper
• Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases

  2025cites this paper
• Immune metabolic changes identify causal candidate genes and enable diagnostic frameworks in MAFLD

  2025cites this paper
• From “Traditional” to “Trained” Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study

  2025cites this paper
• Dual roles of T cells in metabolic dysfunction–associated steatohepatitis pathogenesis and liver fibrosis: From inflammation to therapeutic targets

  2025cites this paper
• MASLD development: From molecular pathogenesis toward therapeutic strategies

  2025cites this paper
• The impact of T cells on immune-related liver diseases: an overview

  2025cites this paper
• Inhibition of Cholesterol Synthesis in T Cells Protects the Liver Against Steatosis, Inflammation, and Oxidative Stress in Metabolic Dysfunction‐Associated Steatohepatitis

  2025cites this paper
• The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC

  2025cites this paper
• Peripheral blood lymphocyte subsets of Chinese adults with liver steatosis

  2025cites this paper
• TIPE2 deficiency amplifies inflammation and immune dysregulation in MASH through modulating hepatic lipid metabolism and immune cell function

  2025cites this paper
• From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma

  2025cites this paper
• Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Inflammation in MASLD progression and cancer

  2025cites this paper
• The spleen-liver axis supports obesity-induced systemic and fatty liver inflammation via MDSC and NKT cell enrichment.

  2025cites this paper
• The Roles of T Lymphocyte Subsets in the Pathogenesis of NAFLD

  2025cites this paper
• Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?

  2025cites this paper
• Interleukin-18 binding protein protects against metabolic steatohepatitis

  2025cites this paper
• A maternal high-fat diet predisposes to infant lung disease via increased neutrophil-mediated IL-6 trans-signaling

  2024cites this paper
• SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation.

  2024cites this paper
• Active role of the immune system in metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Ag-driven CD8+ T cell clonal expansion is a prominent feature of MASH in humans and mice

  2024cites this paper
• Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity

  2024cites this paper
• An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD

  2024cites this paper
• Spatial genomics: mapping human steatotic liver disease

  2024cites this paper
• OMIP‐104: A 30‐color spectral flow cytometry panel for comprehensive analysis of immune cell composition and macrophage subsets in mouse metabolic organs

  2024cites this paper
• The PD-1/PD-L1 Axis in the Biology of MASLD

  2024cites this paper
• Investigating peripheral blood monocyte and T-cell subsets as non-invasive biomarkers for asymptomatic hepatic steatosis: results from the Multi-Ethnic Study of Atherosclerosis

  2024cites this paper
• The double roles of T cell-mediated immune response in the progression of MASLD.

  2024cites this paper
• METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation

  2024cites this paper
• Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent

  2024cites this paper
• Myeloid cell MHC I expression drives CD8+ T cell activation in nonalcoholic steatohepatitis

  2024cites this paper
• Inflammatory processes involved in NASH-related hepatocellular carcinoma

  2023cites this paper
• Decoding the role of immune T cells: A new territory for improvement of metabolic‐associated fatty liver disease

  2023cites this paper
• An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation

  2023cites this paper
• Invited review liver fibrosis in NAFLD/NASH: From pathophysiology towards diagnostic and therapeutic strategies.

  2023cites this paper
• Invariant natural killer T cells in autoimmune cholangiopathies: Mechanistic insights and therapeutic implications.

  2023cites this paper
• Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

  2023cites this paper
• Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions

  2023cites this paper
• The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.

  2023cites this paper
• CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.

  2023cites this paper
• Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD

  2023cites this paper
• Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis

  2023cites this paper
• Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

  2023cites this paper
• Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice

  2023cites this paper
• Mechanisms of liver fibrosis in metabolic syndrome

  2023cites this paper
• State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy.

  2023cites this paper
• Bệnh gan nhiễm mỡ liên quan chuyển hóa (MAFLD): bệnh hệ thống ngoài gan

  2023cites this paper
• A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis

  2023cites this paper
• Multidimensional landscape of non‐alcoholic fatty liver disease‐related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives

  2023cites this paper
• Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Innate-like T lymphocytes in chronic liver disease

  2023cites this paper
• Advancements in MAFLD Modeling with Human Cell and Organoid Models

  2022cites this paper
• T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis

  2022influential citation
• Fatty liver and risk of dementia NAFLD increases a risk of stroke DPP-4 inhibitor-specific biomarkers in NAFLD LPS promotes HCC by NETs formation via TLR4 CLIF-SOFA score and sepsis

  2022cites this paper
• Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

  2022cites this paper
• Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis

  2022cites this paper
• Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.

  2022cites this paper
• Hepatic Stellate Cell-Immune Interactions in NASH

  2022cites this paper
• Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.

  2022cites this paper
• An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues

  2022influential citation
• Immune-metabolic interactions in homeostasis and the progression to NASH.

  2022cites this paper
• Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment.

  2022cites this paper
• Pathogenesis from Inflammation to Cancer in NASH-Derived HCC

  2022cites this paper
• Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells

  2022cites this paper
• Mouse promyelocytic leukemia zinc finger protein (PLZF) regulates hepatic lipid and glucose homeostasis dependent on SIRT1

  2022cites this paper
• A high-trans fat, high-carbohydrate, high-cholesterol diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response

  2022cites this paper
• Advances in T Cells Based on Inflammation in Metabolic Diseases

  2022influential citation
• Crucial role of T cells in NAFLD-related disease: A review and prospect

  2022cites this paper
• Bile Acids: A Bridge Linking Gut Microbiota and NAFLD

  2022cites this paper
• The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity

  2022cites this paper
• Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis

  2021cites this paper
• Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma

  2021cites this paper
• Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease

  2021cites this paper
• Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma

  2021cites this paper
• Intravital imaging of interactions between iNKT and kupffer cells to clear free lipids during steatohepatitis

  2021cites this paper
• Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

  2021cites this paper
• Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease

  2021cites this paper
• Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets

  2021cites this paper
• Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System

  2021cites this paper
• The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

  2021cites this paper
• Rifaximin Prevents T-Lymphocytes and Macrophages Infiltration in Cerebellum and Restores Motor Incoordination in Rats with Mild Liver Damage

  2021cites this paper
• A single-cell transcriptomic atlas characterizes liver non-parenchymal cells in healthy and diseased mice

  2021cites this paper
• Interleukin-10 Attenuates Liver Fibrosis Exacerbated by Thermoneutrality

  2021cites this paper
• XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

  2021cites this paper
• Worldwide flavor enhancer monosodium glutamate combined with high lipid diet provokes metabolic alterations and systemic anomalies: An overview

  2021cites this paper
• T Cell Subsets and Natural Killer Cells in the Pathogenesis of Nonalcoholic Fatty Liver Disease

  2021cites this paper
• The Emerging Role of B Cells in the Pathogenesis of NAFLD

  2021cites this paper
• Chronic treatment with acetaminophen protects against liver aging by targeting inflammation and oxidative stress

  2021cites this paper
• Stress kinases in the development of liver steatosis and hepatocellular carcinoma

  2021cites this paper
• The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis

  2020cites this paper
• The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

  2020cites this paper
• Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

  2020cites this paper
• Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?

  2020cites this paper